JP2017537927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537927A5 JP2017537927A5 JP2017529805A JP2017529805A JP2017537927A5 JP 2017537927 A5 JP2017537927 A5 JP 2017537927A5 JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017537927 A5 JP2017537927 A5 JP 2017537927A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- synergistic
- administered
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087489P | 2014-12-04 | 2014-12-04 | |
| US62/087,489 | 2014-12-04 | ||
| PCT/US2015/063585 WO2016090070A1 (en) | 2014-12-04 | 2015-12-03 | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537927A JP2017537927A (ja) | 2017-12-21 |
| JP2017537927A5 true JP2017537927A5 (enExample) | 2019-01-17 |
Family
ID=55022696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529805A Withdrawn JP2017537927A (ja) | 2014-12-04 | 2015-12-03 | がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170355768A1 (enExample) |
| EP (1) | EP3227335A1 (enExample) |
| JP (1) | JP2017537927A (enExample) |
| KR (1) | KR20170088984A (enExample) |
| CN (1) | CN107249632A (enExample) |
| AU (1) | AU2015358462A1 (enExample) |
| BR (1) | BR112017011538A2 (enExample) |
| CA (1) | CA2969665A1 (enExample) |
| EA (1) | EA201791049A1 (enExample) |
| IL (1) | IL252535A0 (enExample) |
| MX (1) | MX2017007097A (enExample) |
| SG (1) | SG11201704343SA (enExample) |
| WO (1) | WO2016090070A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501254A1 (en) | 2010-12-17 | 2016-07-29 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| CN104918957B (zh) | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| JP2019534292A (ja) * | 2016-11-02 | 2019-11-28 | アペクシジェン， インコーポレイテッド | 組み合わせた抗ｃｄ４０抗体および使用方法 |
| WO2019200462A1 (en) * | 2018-04-16 | 2019-10-24 | Adaerata, Limited Partnership | Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
| JP2024520435A (ja) * | 2021-05-27 | 2024-05-24 | セルジーン コーポレーション | 組み合わせ療法を用いて多発性骨髄腫を治療する方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| HRP20130077A2 (hr) | 1998-12-23 | 2013-07-31 | Pfizer Inc. | Humana monoklonalna protutjela za ctla-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| WO2000050423A1 (en) | 1999-02-22 | 2000-08-31 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | C-21 modified epothilones |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| KR20110017020A (ko) | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US6958115B2 (en) | 2003-06-24 | 2005-10-25 | The United States Of America As Represented By The Secretary Of The Navy | Low temperature refining and formation of refractory metals |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| PT2641601T (pt) | 2006-08-07 | 2016-10-14 | Dana Farber Cancer Inst Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib |
| PL2068930T3 (pl) | 2006-08-07 | 2013-02-28 | Abbvie Biotherapeutics Inc | Kompozycje i sposoby wykorzystujące przeciwciało anty-CS1 do leczenia szpiczaka mnogiego |
| WO2008019379A2 (en) | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010051391A1 (en) | 2008-10-31 | 2010-05-06 | Facet Biotech Corporation | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| WO2011053322A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| EP2493485A1 (en) | 2009-10-30 | 2012-09-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| AU2013263076B2 (en) * | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
-
2015
- 2015-12-03 US US15/531,538 patent/US20170355768A1/en not_active Abandoned
- 2015-12-03 CN CN201580065674.2A patent/CN107249632A/zh active Pending
- 2015-12-03 BR BR112017011538A patent/BR112017011538A2/pt not_active IP Right Cessation
- 2015-12-03 MX MX2017007097A patent/MX2017007097A/es unknown
- 2015-12-03 SG SG11201704343SA patent/SG11201704343SA/en unknown
- 2015-12-03 AU AU2015358462A patent/AU2015358462A1/en not_active Abandoned
- 2015-12-03 CA CA2969665A patent/CA2969665A1/en not_active Abandoned
- 2015-12-03 JP JP2017529805A patent/JP2017537927A/ja not_active Withdrawn
- 2015-12-03 EP EP15816310.5A patent/EP3227335A1/en not_active Withdrawn
- 2015-12-03 EA EA201791049A patent/EA201791049A1/ru unknown
- 2015-12-03 KR KR1020177017909A patent/KR20170088984A/ko not_active Withdrawn
- 2015-12-03 WO PCT/US2015/063585 patent/WO2016090070A1/en not_active Ceased
-
2017
- 2017-05-25 IL IL252535A patent/IL252535A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506403A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| JP2019526595A5 (enExample) | ||
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| JP2015532292A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2016530280A5 (enExample) | ||
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| JP2009518441A5 (enExample) | ||
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| JP2018503610A5 (enExample) | ||
| RU2016151757A (ru) | Антагонисты pdl-1 и pd-1 для лечения hpv-отрицательных форм рака | |
| AR105027A1 (es) | Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos | |
| JP2012193216A5 (enExample) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| FI3464380T3 (fi) | Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma | |
| MX2020012755A (es) | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). | |
| JP2015517511A5 (enExample) | ||
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| JP2018522028A5 (enExample) | ||
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| JP2018519300A5 (enExample) |